A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma
Authors
Keywords
Metastatic melanoma, TEM-1, Tumor endothelial marker-1, Endosialin, Angiogenesis, Ontuxizumab, MORAB-004
Journal
INVESTIGATIONAL NEW DRUGS
Volume 36, Issue 1, Pages 103-113
Publisher
Springer Nature
Online
2017-11-11
DOI
10.1007/s10637-017-0530-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel antibody probes for the characterization of endosialin/TEM-1
- (2016) Daniel J. O’Shannessy et al. Oncotarget
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature
- (2015) Katherine Rybinski et al. Oncotarget
- Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
- (2015) Anna Niezgoda et al. Biomed Research International
- A Review of Novel Therapies for Melanoma
- (2014) Chante Karimkhani et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors
- (2014) L. A. Diaz et al. CLINICAL CANCER RESEARCH
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling
- (2010) Brian Tomkowicz et al. CANCER BIOLOGY & THERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endosialin (Tem1) Is a Marker of Tumor-Associated Myofibroblasts and Tumor Vessel-Associated Mural Cells
- (2008) Sven Christian et al. AMERICAN JOURNAL OF PATHOLOGY
- Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma
- (2008) C. Rouleau et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays
- (2008) Sacha Gnjatic et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
- (2008) R. G. Bagley et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started